Panacos Pharmaceuticals, Inc. (PANC)

0.00 66.67
Prev Close 0.00
Open 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Volume 10.09K
Exchange OTC
Shares Outstanding 53.64B
Market Cap 10.00K
Div & Yield N.A. (N.A)

For Myriad Genetics, the Splice Is Right

Myriad Genetics shares were soaring Tuesday after the firm announced a healthy second quarter that beat analyst expectations.

Biotech Stock Mailbag: Panacos

Panacos is worth more than 12 cents -- and is worth hanging on to.

Biotech Mailbag: Savient's Unsavory Surprise

Savient Pharmaceuticals on Monday released new safety data linking its gout drug Puricase to serious cardiovascular side effects.

Feuerstein's Biotech-Stock Mailbag: Panacos

Confessions of a former Panacostal; weighing Indevus' chances after its latest FDA blow; and more Elan.

Biotech Notebook: Medarex, Panacos, Advanced Life

Medarex refuses to face reality about the trial failure of its skin cancer drug.

Friday's Health Winners & Losers

Immucor slumps on an FTC investigation.

Thursday's Late Winners & Losers

Microsoft led the after-hours charge, following an earnings beat.

Feuerstein's Biotech-Stock Mailbag

This week: Biogen Idec and Neurocrine Biosciences.

Tuesday's Health Winners & Losers

Panacos falls on the departure of its CFO as well as a downgrade.

Tuesday's Small-Cap Winners & Losers

McCormick & Schmick's slides on lowered guidance.

Panacos Pharma CFO Resigns

Peyton Marshall leaves to 'pursue other opportunities.'

Biotech Dustbin Yields Winners

Abandoned by investors, Genelabs and Panacos Pharma are worth a second look.

Wednesday's Late Winners & Losers

Hoku Scientific climbs on news of a signed contracted.

Avexa Data's Ripple Effect

Positive results from Australia could mean big things in the U.S.

Tuesday's Early Winners & Losers

Wireless Facilities falls after saying it needs to restate results.

Fretting Dow Theory

FedEx's miss gets folks worried about 'non confirmation'. Plus, the M&A wave rolls on.

Wednesday's Early Winners & Losers

Panacos falls on disappointing study data for its HIV treatment.

Thursday's Health Winners & Losers

Shares of Anadys Pharmaceuticals drop after the company announces the planned departure of its CEO.

Today's Early Winners and Losers

Charles & Colvard issues a first-quarter sales warning, sending shares sliding.

Wal-Mart Headed for a Major Markup

If history is a guide, the stock could be gearing for another major rise. Plus the Nasdaq, NetEase and more.

An Indelible Drop for Dell?

Its chart indicates as much. Plus charts on the Nasdaq, Panacos, Charles Schwab, and more.

Health Stocks in Motion

Wright Medical falls following the resignation of its CEO.

SanDisk May Be Worth a Re-Up

The stock is near the top of an uptrend channel. Plus the Nasdaq, Abgenix and more.

A Binge in Biotech M&A Looms

Big drugmakers are pursuing biotech outfits and making the small fry more willing to sell.

Cramer's 'Mad Money Lightning Round': Not Calling Avon

Also, Banco Bradesco is muy caliente.

Panacos Priced to Perform

The biotech's shares are underpriced, and its HIV drug holds great promise.

Cramer's 'Mad Money Lightning Round': Dell's a Tough Call

Cramer says it's worth waiting for this stock to drop down before buying.

Brazilian Storm Clouds Lift, for Now

There's little fallout Monday from a scandal that rocked the nation's financial markets Friday.

Health Stocks in Motion

Biolase believes shareholders will be better served by eliminating its dividend.